Reactive oxygen species (ROS) are highly reactive chemical species containing oxygen,
controlled by both enzymatic and nonenzymatic antioxidant defense systems. In the heart …

Doxorubicin is utilized for anti-neoplastic treatment for several decades. The utility of this
drug is limited due to its side effects. Generally, doxorubicin toxicity is originated from the …

Doxorubicin (DOX) is the most widely used anthracycline anticancer agent; however, its
cardiotoxicity limits its clinical efficacy. Numerous studies have elucidated the mechanisms …

Objectives The frontline drug doxorubicin has been used for treating cancer for over 30
years. While providing a cure in select cases, doxorubicin causes toxicity to most major …

Doxorubicin (DOX) is an anticancer anthracycline that presents a dose‐dependent and
cumulative cardiotoxicity as one of the most serious side effects. Several hypotheses have …

Established doxorubicin cardiomyopathy is a lethal disease. When congestive heart failure
develops, mortality is approximately 50%. Extensive research has been done to understand …

First isolated in the early 1960s, doxorubicin (DOX) remains among the most effective
anticancer drug ever developed. However, this drug has proven to be a double-edged …

Chemotherapy‐induced cardiotoxicity is a serious complication that poses a serious threat
to life and limits the clinical use of various chemotherapeutic agents, particularly the …

Homeostatic regulation of cardiomyocytes plays a crucial role in maintaining the normal
physiological activity of cardiac tissue. Severe cardiotoxicity results in cardiac diseases …

Doxorubicin (DOX) is one of the most widely used and successful antitumor drugs, but its
cumulative and dose-dependent cardiac toxicity has been a major concern of oncologists in …